RxDoctor Payments DataLook up a doctor →

Jason Handza, DO

Retina Specialist · Pinellas Park, FLNPI 1083603146

Payments from drug & device makers

$1,335,742in general payments, 2019–2025

Across 528 payments — averaging $2529.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$688K
  • Apellis Pharmaceuticals, Inc.$200K
  • Kyowa Kirin, Inc.$191K
  • Novartis$113K
  • Bayer$91K
  • Hexal AG$46K
  • plus $6K from 19 others

What the payments were for

  • Speaking & faculty fees$4048%
  • Travel & lodging$83117%
  • Food & beverage$3,66575%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,335,742 in reported general payments places this provider in the 90th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$1,011,667
Medicare patients
302
Services billed
10,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept337$737,264
Eylea HdAflibercept239$698,113
VabysmoFaricimab-Svoa78$180,701
IzervayAvacincaptad Pegol Sodium/Pf41$117,499
SyfovrePegcetacoplan/Pf33$117,236
LucentisRanibizumab26$62,564
OzurdexDexamethasone15$21,998
Ketorolac Tromethamine49$1,862
Prednisolone Acetate15$823
Brimonidine Tartrate11$295
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$221
Latanoprost17$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd$609$1,435,377576 claims
Genentech USA, Inc.Vabysmo$449$180,70178 claims
Astellas Pharma US IncIzervay$184$117,49941 claims
Apellis Pharmaceuticals, Inc.Syfovre$200,342$117,23633 claims
AbbVieOzurdex$744$21,99815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Pinellas Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →